Abstract
At homeostasis, vascular cells display a very low proliferative rate and a scant migratory activity. However, hyperplastic growth and locomotion of vascular cells are a hallmark of vascular remodeling during several pathophysiological conditions (e. g., neovascularization, arteriosclerosis and restenosis post-angioplasty). Thus, a better understanding of the molecular mechanisms that control vascular cell proliferation and migration should facilitate the development of novel therapies to treat cardiovascular disease. In this review, we will discuss recent studies implicating the cell cycle regulatory protein p27Kip1 as a key modulator of vascular cell growth and locomotion in vitro and during vascular remodeling in vivo.
Keywords: atherosclerosis, restenosis, neovascularization, proliferation, migration, p27
Current Vascular Pharmacology
Title: Role of the Growth Suppressor p27Kip1 During Vascular Remodeling
Volume: 1 Issue: 1
Author(s): Antonio Díez-Juan, Claudia Castro, M. D. Edo and Vicente Andrés
Affiliation:
Keywords: atherosclerosis, restenosis, neovascularization, proliferation, migration, p27
Abstract: At homeostasis, vascular cells display a very low proliferative rate and a scant migratory activity. However, hyperplastic growth and locomotion of vascular cells are a hallmark of vascular remodeling during several pathophysiological conditions (e. g., neovascularization, arteriosclerosis and restenosis post-angioplasty). Thus, a better understanding of the molecular mechanisms that control vascular cell proliferation and migration should facilitate the development of novel therapies to treat cardiovascular disease. In this review, we will discuss recent studies implicating the cell cycle regulatory protein p27Kip1 as a key modulator of vascular cell growth and locomotion in vitro and during vascular remodeling in vivo.
Export Options
About this article
Cite this article as:
Díez-Juan Antonio, Castro Claudia, Edo D. M. and Andrés Vicente, Role of the Growth Suppressor p27Kip1 During Vascular Remodeling, Current Vascular Pharmacology 2003; 1 (1) . https://dx.doi.org/10.2174/1570161033386709
DOI https://dx.doi.org/10.2174/1570161033386709 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Editorial (Hot Topics: New Insights in the Pathogenesis and Treatment of Diabetic Retinopathy)
Current Medicinal Chemistry The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Purification and Characterization of a Novel Anti-Proliferative Lectin from Morus alba L. Leaves
Protein & Peptide Letters Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Oxidative stress and myocarditis
Current Pharmaceutical Design Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease
Current Cardiology Reviews Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases
Current Pharmaceutical Biotechnology Active Coatings: Examples and Applications
Recent Patents on Mechanical Engineering Aqueous Extract of Arbutus unedo Inhibits STAT1 Activation in Human Breast Cancer Cell Line MDA-MB-231 and Human Fibroblasts Through SHP2 Activation
Medicinal Chemistry Overlaps in the Nosology of Substance Abuse and Overeating: The Translational Implications of “Food Addiction”
Current Drug Abuse Reviews An Expanding Role of Biomarkers in Pulmonary Arterial Hypertension
Current Pharmaceutical Biotechnology The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View
Reviews on Recent Clinical Trials Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Current Medicinal Chemistry Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Adverse Drug Reactions and Safety Considerations of NSAIDs: Clinical Analysis
Current Drug Safety